Address
Road no. 4, Vatara, Notun Bazar
Dhaka, Bangladesh
Address
Road no. 4, Vatara, Notun Bazar
Dhaka, Bangladesh

Product Name: Ascimib
Generic Name: Asciminib
Strength: 40 mg
Volume: 30 tablets
Manufacturer: Everest Pharmaceutical
Asciminib 40 mg tablet (Ascimib) is used to treat certain types of blood cancer, such as Philadelphia chromosome-positive chronic myeloid leukemia (PH+ CML) in chronic phase, in adult patients who have already taken two or more inhibitors.
When two chromosomes swap their places and then a new abnormal chromosome is created, called the Philadelphia chromosome, that affects bone marrow production and changes white blood cells, causing leukemia.
In some cases, this medication is effective in treating the resistant mutation T315I. Healthcare providers may use this medication in other treatments also.
“On October 29, 2024, the Food and Drug Administration granted accelerated approval to asciminib (Scemblix, Novartis AG) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).”
Ascimib 40 mg is a STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor, different from traditional kinase inhibitors. When the Philadelphia chromosome is created, it creates a fusion between genes BCR-ABL1. It works by inhibiting the ABL1 part and helps prevent bone marrow from producing abnormal white blood cells.
The recommended dose is 40 mg twice daily as monotherapy or 80 mg in certain patients according to the healthcare provider’s prescription. It is an orally administrable medication that should be taken without food at the same time every day. There should be a minimum gap of 12 hours between each dose. Swallow the tablets with water; do not chew, crush, or split them.
Common side effects are listed below. Inform your healthcare provider if any of these happen.
Ascimib tablet should be taken without food, because food can decrease the absorption of the medicine in your body. And it is still unknown if drinking alcohol affects the absorption of the medication or not.
Yes, this medication may interact with some other drugs, lowering the blood level in the body, decreasing the absorption in the body, and may also create some adverse side effects. Always check with your doctor if you are using any other medication, prescription, non-prescription, or herbal. The list below represents some common medications that interact with Ascimib 40 mg.
If you are not sure your other medication will interact with the Ascimib, you can check it here.
Check drug interactions at trusted medical resources or consult your healthcare provider.
Patients who are allergic to any of the ingredients of Asciminib should avoid the medication with their healthcare provider’s consultation.
Tell your healthcare provider about all of your health conditions, like as you had any severe diseases before, and all the medications you are taking.
If you are breastfeeding, your healthcare provider may not suggest that you take Asciminib as it may harm the infant.
Tell your doctor if you are pregnant or planning to get pregnant, as they may not suggest getting pregnant during the treatment. Ingredients in the medication may harm the unborn baby. To avoid unwanted pregnancy, use proper contraception for both males and females.
Asciminib 40 mg may cause problems with fertility; consult your healthcare provider before taking it.
Asciminib 40 mg tablet price depends on the manufacturer, brand, location, availability, and supply. This prescription medicine is only available at licensed medical shops, authorized local and international distributors, and through manufacturers. It is the only prescription medicine, and you can not buy it over the counter. Always consult with your healthcare provider before buying any prescription medicine online.
Asciminib 40 mg tablet is an effective targeted therapy for adults with Philadelphia chromosome–positive chronic myeloid leukemia, including those resistant to prior tyrosine kinase inhibitors. Clinical trials supporting the FDA accelerated approval demonstrated its ability to achieve meaningful hematologic and molecular responses, including in patients with the T315I mutation. When used under medical supervision with proper monitoring, Ascimib provides a valuable option for managing chronic-phase CML safely and effectively.
Reviews
There are no reviews yet.